

Lazard

Select Australian Equity Fund

May 2023
Factsheet

High Conviction

Benchmark unconstrained, with high active share and best ideas

Disciplined 'Value' Investment Approach

Longer-term Independent thinking

Stability and Experience

Team together at Lazard for more than 20 years

Performance² (%)

	Lazard	Index	Excess Return
1 Month	-2.2	-2.5	0.3
3 Months	-1.0	-0.9	-0.1
1 Year	8.2	2.9	5.3
3 Years (pa)	17.7	11.4	6.3
5 Years (pa)	7.1	7.5	-0.4
10 Years (pa)	8.5	8.1	0.4
Since Inception (pa)	9.2	8.5	0.7

Investment Characteristics

	Lazard	Index
Price/Cash Flow	5.9	9.2
Price/Book Value	1.4	2.0
Dividend Yield (%)	5.4	4.6
Forward Price/Earnings	11.6	14.5
Active Share (%)	78.7	-
3 Year Turnover (%pa)	44.8	-

Fund Facts

Number of stocks	29
Total Fund Size	\$70.2m
Inception Date	22 August 2002
Total Management Costs	W Class: 0.90% p.a.
Index	S&P/ASX 200
Minimum Investment	\$20,000
Buy/Sell Spread	0.20%/0.20%
Distributions	Quarterly ¹
APIR Code	LAZ0013AU


Allocations (%)

Sector	Lazard	Index	Overweight/Underweight
Communication Services	0.0	4.2	-4.2
Consumer Discretionary	9.2	6.4	2.8
Consumer Staples	12.6	4.9	7.7
Energy	17.1	5.7	11.4
Financials	29.6	27.0	2.6
Health Care	3.0	10.6	-7.6
Industrials	10.9	6.5	4.4
Information Technology	0.0	3.1	-3.1
Materials	12.6	23.8	-11.2
Real Estate	4.2	6.3	-2.1
Utilities	0.0	1.5	-1.5
Cash	1.0	0.0	1.0

Top 5 Holdings (%)

	Lazard	Index
QBE Insurance	10.1	1.0
Woodside Energy	9.3	3.1
AMP	7.0	0.2
Rio Tinto	6.5	1.9
Santos	6.2	1.2

Down Market Capture Ratio



Down Market Capture Ratio is calculated since inception and based on performance net of all fees. Down Market Capture is a statistical measure of an investment manager's overall performance in down markets, being calendar months where the Index experiences negative performance. A drawdown ratio (or percentage) of less than 100 (or 100%) reflects that the manager has outperformed the Index during such down markets.



¹ Distributions are made quarterly if of an economic size.

Performance is presented net of W Class fees, please refer to www.lazardassetmanagement.com for performance of the I Class.

Investments can go up and down. Past performance is not necessarily indicative of future performance. Net returns are quoted after the deduction of Management Costs. Performance assumes reinvestment of all distributions.

Commentary

Australian equities fell through May 2023 with the S&P ASX 200 index closing down -2.5% for the month, on continued rate hike expectations from central banks and concerns around US law makers intentions on the country's debt ceiling. Australian 10-year bond yields sold off by 0.26bps to 3.60%, on the resumption of rate hikes by the Reserve Bank of Australia to 3.85% in the May 2023 meeting. On a sector basis, Information Technology was the strongest performer, while Utilities and Energy also outperformed. The Consumer Staples and Consumer Discretionary sectors were the relative worst performers.

During the month ended May 2023, the Lazard Select Australian Equity Fund returned -2.2% (net of W Class fees), outperforming the S&P/ASX 200 Accumulation Index which declined -2.5%.

Contributors to Performance

- Aurizon's (AZJ) shares rose 3% during the month outperforming a declining market. Early in the month the company presented at the Macquarie Conference where earnings guidance for the 2023 financial year was confirmed. With an increasing number of earnings downgrades in the market due to an apparent slowing in consumer spending, these earnings were welcomed by the market. We continue to favor Aurizon's defensive earnings profile, cash generation ability as well as the growth supplement from the Bulk division. We believe the market continues to price the company on very modest expectations, as we continue to hold our positions.
- Costa Group's (CGC) share price outperformed during the month with the shares rising 3% while the market declined about 3%. On the 25 May 2023, the company gave a positive qualitative update specifically noting strength in the international berry business in China and Morocco as well as in the recently acquired 2PH citrus assets. After several years of disappointing earnings, this positive news was well received by the market. We continue to believe that CGC's assets can earn profits materially higher than what has been produced in recent history. If this expectation is confirmed through the results we expect, we expect CGC share price to perform strongly. We continue to be invested in the company.

Detractors from Performance

- Mayne Pharma (MYX) underperformed the market in May. Earlier during the month, the company released a Market Update to 3Q'FY23 and announced an on-market share-buyback of up to 10% of the issued share capital. The trading update confirmed the net cash balance and highlighted that all the businesses were now delivering positive EBITDA. Within Women's Health, Nextstellis is expected to reach breakeven during 1HFY24. Despite the recent share price underperformance in May, the trading update provided comfort to our thesis that MYX is significantly undervalued.
- Whitehaven Coal's (WHC) share price fell during the month due to mild weather in Europe and Asia, which led to weaker energy demand. The benchmark Newcastle coal price also dropped from over US\$200/t to US\$135/t by the end of May 2023. However, due to a lag between spot price and realized price, Whitehaven Coal's earnings will likely continue to benefit from high prices earlier in the year for the next three months. Currently, the global energy market is balanced with demand recovery in Europe and Asia has been slower than expected, while supply has normalized after strong weather events earlier this year. The fund now holds a small position in WHC after taking profit on its strong performance over the past 12 months. Our valuation captures spot coal prices for the next six to twelve months and remains anchored to our long-term coal price assumption of US\$85/t for Newcastle 6,000kcal/kg coal. Whitehaven Coal still appears relatively attractive with around A\$2.5bn in cash (about half its market cap) and 35% completion of its on-market buyback program.

Outlook

2022 saw a dramatic change in market leadership with high multiple stocks falling sharply and modestly priced, strong cash flow businesses performing well. Given the extreme valuation starting point in the second half of 2021 - with valuation dispersions exceeding the TMT bubble peak in early 2000 – we believe the normalisation of valuations appears to be only one third to halfway complete. This process should, in our view, continue in 2023 and beyond, providing a potential tailwind for our portfolios, although history suggests that as inevitable as this normalisation may be, it might not follow a straight-line path. In response to high inflation, 2022 saw the fastest interest rate increases in living memory, which we expect to impact economies progressively through 2023. These two forces, valuation normalisation and a slowing economy, are likely to dominate equity markets in the year ahead. From a sector perspective we continue to view energy positively, given the underinvestment in supply which is likely to result in higher prices and cashflows for producers for an extended period. Insurance companies should also farewell, given earnings tailwinds from strong premium growth and higher bond yields. We remain generally cautious of cyclical exposures, given economic risks for the year ahead, but we will as always be looking for attractive entry points.

What has become increasingly clear is how unusual the investment regime was in the 2010s. The key features of that period, low inflation, zero bound interest rates, perpetual quantitative easing and negative yielding bonds today already appear as extreme and unusual as long-run history suggests they indeed were. The early 2020s is seeing the establishment of a new investment regime which will likely require a different approach. As with all secular changes, the market has only begun to adjust to the new environment. This delayed market recognition is providing significant opportunities and in a relative sense, we look forward to the year ahead with high expectations.

For more information, call us on 1800 825 287
or visit www.lazardassetmanagement.com.au

Disclaimer

The information in this Fact Sheet was prepared by Lazard Asset Management Pacific Co ABN 13 064 523 619, AFS License 238432, and should not be considered a recommendation to purchase, sell or hold any particular security. Securities and sectors mentioned in this Fact Sheet are presented to illustrate companies and sectors in which the Fund may invest. Holdings are subject to change daily. This Factsheet has been prepared without taking account of any investor's objectives, financial situation or needs. Investors should get professional advice as to whether investment in the strategy is appropriate having regard to their particular investment needs, objectives and financial circumstances before investing. Lazard has prepared a target market determination (TMD) for the Lazard Select Australian Equity Fund ('Fund') which sets out the class of consumers for whom the Fund, including the Fund's key attributes, would likely be consistent with their likely objectives, financial situation and needs. A copy of the TMD is available at www.lazardassetmanagement.com, by contacting investorqueries@lazard.com, or from their IDPS operator. It is recommended that investors consider whether their objectives, financial situation and needs are consistent with the target market of the Fund. Investors should obtain a copy of the current Product Disclosure Statement (PDS) for the Fund, available at www.lazardassetmanagement.com, by contacting investorqueries@lazard.com, or from their IDPS operator and should consider the PDS before making any decision about whether to acquire or to continue to hold the Fund. Neither Lazard nor any member of the Lazard Group, including Lazard Asset Management LLC and its affiliates guarantees in any way the performance of the strategy, repayment of capital from the strategy, any particular return from or any increase in the value of the strategy.

The Lonsec (assigned September 2022) presented in this document is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445. The Rating is limited to "General Advice" (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial product(s). Past performance information is for illustrative purposes only and is not indicative of future performance. It is not a recommendation to purchase, sell or hold Lazard Asset Management Pacific Co. product(s), and you should seek independent financial advice before investing in this product(s). The Rating is subject to change without notice and Lonsec assumes no obligation to update the relevant document(s) following publication. Lonsec receives a fee from the Fund Manager for researching the product(s) using comprehensive and objective criteria. For further information regarding Lonsec's Ratings methodology, please refer to our website at: <https://irate.lonsec.com.au/page/ResearchMethodology>

The Zenith Investment Partners ("Zenith") ABN 27 103 132 672 rating (assigned June 2022) referred to in this document is limited to "General Advice" (as defined by the Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Zenith usually charges the product issuer, fund manager or a related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessment's and at <http://www.zenithpartners.com.au/RegulatoryGuidelines>